Market Research Report
Global Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||756746|
|Published||Content info||111 Pages
Delivery time: 1-2 business days
|Global Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market 2019-2023|
|Published: December 3, 2018||Content info: 111 Pages||
The rising partnerships to gain prominence in the market. Vendors are entering into strategic alliances and partnerships for integration of available and emerging technologies into their products. Such partnerships will help the market to grow. Technavio's analysts have predicted that the continuous subcutaneous insulin therapy devices market will register a CAGR of more than 9% by 2023.
The rise in prevalence of diabetes has resulted in increasing awareness efforts by various organizations globally. Programs such as the Diabetes Activities Under State Public Health Actions increase the participation of people.
The growth of the market is hindered by product recalls. Product recalls affect the sales of a company negatively, which results in a decline in it market share. Also, they affect the brand image of vendors, thereby reducing profit margins.
For the detailed list of factors that will drive and challenge the growth of the continuous subcutaneous insulin therapy devices market during the 2019-2023, view our report.
The market appears to be concentrated and with the presence of several companies including Medtronic and Tandem Diabetes Care the competitive environment is quite intense. Factors such as the rising partnerships and the rise in awareness about diabetes, will provide considerable growth opportunities to continuous subcutaneous insulin therapy devices manufactures. Cellnovo, F. Hoffmann-La Roche, Insulet, Medtronic, and Tandem Diabetes Care are some of the major companies covered in this report.